SOUMYA PHILIP: Open Payments
NPI 1750866133 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 36 payments from 10 companies in 2025. Trend: 2023 $820 · 2024 $866 · 2025 $781
Food & beverage: $782
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $199 |
| Amgen Inc. | 9 | $158 |
| BridgeBio Pharma, Inc. | 3 | $95 |
| Novartis Pharmaceuticals Corporation | 3 | $81 |
| E.R. Squibb & Sons, L.L.C. | 3 | $72 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $55 |
| Cleerly, Inc. | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
| CVRx, Inc. | 1 | $11 |
Products named: FARXIGA, REPATHA, Attruby, LEQVIO, ELIQUIS, JARDIANCE, Kerendia, WAINUA.
Industry payments across TX — which companies pay providers there.
